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Currently, there is no evidence whether ganciclovir, or its oral prodrug valganciclovir, penetrates into the
cerebrospinal fluid of human infants treated for congenital cytomegalovirus infection. Here, we report a case study
providing evidence that ganciclovir, administered as valganciclovir, reaches the infant’s cerebrospinal fluid when
used at the currently recommended dose for congenital cytomegalovirus infection.
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Ganciclovir (GCV) is the drug of choice for the treatment
of congenital cytomegalovirus (CMV) infection. In fact,
6 weeks intravenous GCV therapy, compared with no treat-
ment, has been demonstrated to significantly prevent hear-
ing deterioration [1] and developmental delays [2] in
infants with congenital CMV infection involving the central
nervous system. Valganciclovir (V-GCV), an oral pro-drug
of GCV, nowadays represents a valuable alternative to GCV
and, compared to GCV, does not require prolonged
hospitalization and catheterization, thus avoiding consider-
able costs for the Health Care System, and infectious risks
for the infants [3]. For both these drugs, cerebrospinal fluid
(CSF) penetration has never been demonstrated in congeni-
tally CMV infected infants undergoing antiviral therapy at
the currently recommended dosages.
Case report
A 30-year-old woman had a primary CMV infection in
the first trimester of pregnancy (gestation week 9), de-
fined by the presence of immunoglobulin (Ig) M and
low avidity IgG. At gestation week 20, CMV DNA was* Correspondence: fab.natale@libero.it
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of 3.8 × 105 genomic copies (GC)/mL. Intrauterine
growth retardation was detected starting gestation week
30. A foetal brain magnetic resonance imaging (MRI),
performed two weeks later, was normal. A small for ges-
tational age (<10° centile for gestational age) female
infant in good clinical conditions was delivered at
38 weeks gestational age. Congenital CMV infection was
confirmed by means of quantitative Polymerase Chain
Reaction (qPCR) performed on urine sampled on day of
life (dol) 2.
On dol 11, the infant was referred to our centre to
undergo a diagnostic workup for congenital CMV infection.
Clinical examination, fundus oculi, abdominal and cerebral
ultrasound, and auditory brainstem evoked responses were
all negative; complete blood count and transaminase levels
were in the normal range for the infant’s age. Of note, a
brain MRI performed at 1.5 Tesla (Magnetom Avanto, Sie-
mens Medical Solution, Malvern, PA, USA) failed to find
any brain lesions. CMV DNA search was performed on
urine and blood samples by an automated system for nu-
cleic acid extraction (Nuclisens EasyMag, Biomerieux) and
a commercially available TaqMan Real Time Polymerase
Chain Reaction kit (ELITech Group S.p.A.) for quantitative
CMV DNA amplification. According to our screening pro-
cedure, and following informed consent by the parents, a
lumbar puncture for cerebrospinal fluid (CSF) CMV DNAThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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detected in all the samples tested (Table 1).
Since the CMV-DNA search in the CSF was positive,
on dol 20 we decided to start antiviral treatment with a
commercial oral solution of V-GCV (Valcyte®, Roche S.
p.A., Segrate, Italy) at 16 mg/kg/dose twice a day. On
dol 21, after the uneventful administration of two doses
of V-GCV, the baby was discharged home. The drug
dosage was adjusted weekly according to the weight in-
crease. During V-GCV therapy, complete blood count,
transaminase, and creatinine levels were monitored three
times (on dol 27, 45, and 55 respectively) for possible
drug toxicity: the first two blood tests were within the
normal range for the patient’s age whereas, on dol 55, a
remarkable transaminase increase was detected (Alanine
aminotransferase: 328 U/L, Aspartate Aminotransferase:
400 U/L). Due to the onset of liver toxicity presumably
related to antiviral therapy, V-GCV was withdrawn on
dol 55 (after 35 days of therapy) and never resumed. Fif-
teen days later, transaminase levels were in the normal
range.
CMV DNA qPCR on plasma, urine and CSF samples
were again performed on dol 45 (Table 1). At the same
time, plasma trough and peak values (one hour before and
two hours after V-GCV administration, respectively) and
CSF GCV concentration (performed concomitantly with
GCV plasma trough sample) were evaluated by means of
High-Performance Liquid Chromatography assay with
fluorescence detection (Table 1). Ongoing clinical, oph-
thalmological, audiological and neurological follow-up (by
means of the Bayley Scales of Infant Development-III) is
normal at twelve months of age.Table 1 Summary of the laboratory findings obtained on
cerebrospinal fluid, blood, and urine samples before (dol
11) and after 25 days of Valganciclovir therapy (dol 45)
Findings Dol 11 Dol 45
Cerebrospinal Fluid
Proteins 67,9 mg/dL 59,0 mg/dL
White Cells 12 cells/μL 9 cells/μL
Red Cells 141 cells/μL 373 cells/μL
CMV-DNA 2.835.371 GC/ml Negative
GCV - 0,52 μg/ml
Blood
CMV-DNA 115.068 GC/ml 821 GC/ml
GCV (trough) - 0,53 μg/ml
GCV (peak) - 5,54 μg/ml
Urine
CMV-DNA >25.000.000 GC/ml 619.137 GC/ml
See text for the abbreviations.Discussion
A randomized, controlled trial, demonstrated that gan-
ciclovir, administered at 6 mg/kg/dose twice a day for
6 weeks intravenously, is able to prevent hearing deteri-
oration [1] and developmental delays [2] in infants with
congenital CMV infection involving the central nervous
system. V-GCV, an oral pro-drug of ganciclovir that is
rapidly converted into ganciclovir after intestinal ab-
sorption, reached plasma concentrations comparable to
those achieved with administration of intravenous gan-
ciclovir when used at 16 mg/kg/dose twice a day [4]. V-
GCV has demonstrated to be well tolerated and is in-
creasingly used because, compared to GCV, it does not
require hospitalization and catheterization, thus avoid-
ing considerable costs for the Health Care System and
infectious risks for the infants. Moreover, V-GCV seems
to be suitable for prolonged home therapy [3].
The evaluation of CSF levels is used to predict brain
interstitial fluid concentrations of a drug [5]. Although
GCV penetration into the CSF has been demonstrated
in some reports dealing with CMV infected adults and
children in different clinical situation (an adult suffering
renal failure [6], a child with acute lymphoblastic leukemia
who exhibited a reduced creatinine clearance [7], and two
bone marrow transplanted patients on different ganciclo-
vir regimen therapy [8]), our report provides evidence, for
the first time, that GCV, administered as V-GCV, reaches
the infant’s CSF when used at the currently recommended
dosages for congenital CMV infection [4]. Our GCV
plasma trough and peak concentrations (Table 1), detected
by means of a validated technique [9], were consistent
with those reported in the medical literature [3]; GCV
plasma (trough value) and CSF levels (trough value) were
overlapping in this case (Table 1), although additional re-
sults are needed to establish any significant pharmacoki-
netic correlation between plasma and CSF GCV
concentrations in neonates.
CMV DNA qPCR performed on CSF before and during
V-GCV therapy (Table 1) showed a reduced viral load in
the CSF, suggestive of effective therapy on brain infection.
Although the CSF GCV concentration of 0,52 μg/ml we re-
ported was below the inhibitory concentration (IC) 50 for
most CMV clinical isolates [10], it must be taken into ac-
count that the CSF sample was drawn concomitantly with
the plasma trough sample, thus allowing a GCV CSF peak
level over the requested IC 50. Besides, the CSF CMV
DNA negativisation cannot be fully explained since the per-
sistence of CMV DNA into the CSF of untreated infants is
unknown.
According to published guidelines [11], and in order
to prevent possible ongoing brain damage resulting from
CMV replication in the infant’s brain, we decided (fol-
lowing the parents’ informed consent) to start V-GCV
therapy in this patient given the positive CSF CMV
Natale et al. Italian Journal of Pediatrics  (2015) 41:26 Page 3 of 3DNA and despite normal CSF indices (Table 1) and neuro-
imaging. Nonetheless, in our opinion, further studies are
necessary to evaluate the need for therapy, if any, in infants
with positive CSF CMV DNA and undetectable brain
damage.
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